CClinicalTrials.gg
Active, not recruitingNCT06098001Updated Oct 24, 2023

Bioavailability Study of Hemp Phenolics

An interventional study of Low dose dietary fiber and High dose dietary fiber in Bioavailability, Metabolites and Excretion, sponsored by Brightseed. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-24.

Sponsored by Brightseed · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Nov 2023, 2 years 11 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The aim is to determine the bioavailability of the polyphenol fraction form a commercially available hemp hull fiber at two different amounts in generally healthy adults. Additional objectives include determining specific metabolites produced over a 24 to 48-hour period following the hemp fiber consumption. Subjects will consume a study pudding that will be used to deliver a low and a high dose fiber product. Blood samples will be collected to measure background levels of metabolites. At day 0 participants will consume a low dose study product and day 6 the high dose study product and provide blood samples over an 8 hr period after study product consumption, to be followed by a 24 hr blood sample and 48 hr blood sample. Additionally following the low / high dose study product 24 and 48 h urine samples will be collected.

02

Conditions studied

  • Bioavailability
  • Metabolites
  • Excretion
03

In context

Lead sponsor

Brightseed is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • BMI 18.50 - 29.99
  • non Tobacco or vaping user
  • non-user of hemp products within 12 months of first visit
  • Willing to stop dietary supplement use within 7 days of visit
  • Generally heathy

Exclusion criteria

Exclusion Criteria:

  • History or presence of clinically important disorders that may affect subjects ability to participate in the study
  • Clinically important GI conditions that potentially interfere with evaluation of study product
  • Uncontrolled hypertension or unstable use of antihypertensives
  • Recent antibiotic use
  • extreme dietary habits
  • recent or currently on weight loss regimen
  • Known allergy or sensitivity to the study products
  • History or presence of cancer in prior 2 years, except for non-melanoma skin cancer
  • History of any major trauma or major surgical event within 2 months of first visit
  • Pregnancy or willing to become pregnant during study
  • Alcohol abuses
  • Exposure to any non-registered drug product within 30 days prior to first visit
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Active comparator
    Low dose fiber

    Dose esacalation design

    Dietary Supplement: Low dose dietary fiber

  • Active comparator
    High dose of fiber

    Dose escalation design which is one arm with low and followed by high dose

    Dietary Supplement: High dose dietary fiber

Interventions

  • Dietary supplementLow dose dietary fiber

    Subjects will receive a low dose or high dose of the dietary fiber product in a dose esacalation design

  • Dietary supplementHigh dose dietary fiber

    Subjects will receive a low dose or high dose of the dietary fiber product in a dose escalation design

06

What researchers measure

Primary outcomes

  1. Blood concentration of phenolics from 0 to 8 hours

    Time frame: 0 to 8 hours after consumption

Secondary outcomes

  1. Blood concentration of phenolics 0 to 24 hours

    Time frame: 0 to 24 hours after consumption

  2. Urine concentration of phenolics 24 and 48 hours after consumption

    Time frame: cumulative total phenolics at 24 and 48 hours

  3. Concentration of Phenolic metabolites in blood and urine

    Time frame: Blood concnetrations at 0 to 8 hours post consumption and cumulative urine concentration 24 hours and 48 hours post consumption

07

Study locations

1 site
  • Biofortis
    Addison, Illinois 60101, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06098001
Lead sponsor
Brightseed
Collaborators
Biofortis Mérieux NutriSciences, University of Arkansas
Responsible party
Sponsor
First posted
Oct 24, 2023
Start date
Sep 15, 2023
Primary completion
Nov 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Oct 24, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion